NEW YORK ─ Massachusetts Institute of Technology spinout Glympse Bio said on Wednesday that it has closed an oversubscribed $46.7 million Series B financing round.
The Cambridge, Massachusetts-based firm said it anticipates using the proceeds to support the continued development of its biosensor platform for the diagnosis of cancers, infectious diseases, and fibrotic diseases such as non-alcoholic steatohepatitis (NASH).